1. Home
  2. LOMA vs CGEM Comparison

LOMA vs CGEM Comparison

Compare LOMA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loma Negra Compania Industrial Argentina Sociedad Anonima ADS

LOMA

Loma Negra Compania Industrial Argentina Sociedad Anonima ADS

HOLD

Current Price

$11.61

Market Cap

1.4B

Sector

Industrials

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$16.46

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOMA
CGEM
Founded
1926
2016
Country
Argentina
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.1B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
LOMA
CGEM
Price
$11.61
$16.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$15.00
$30.13
AVG Volume (30 Days)
344.0K
553.4K
Earning Date
05-04-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$27.53
N/A
Revenue Next Year
N/A
$5.20
P/E Ratio
$187.97
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.04
$5.68
52 Week High
$13.20
$19.43

Technical Indicators

Market Signals
Indicator
LOMA
CGEM
Relative Strength Index (RSI) 50.83 47.07
Support Level $11.37 $16.00
Resistance Level $12.18 $19.10
Average True Range (ATR) 0.45 0.91
MACD 0.02 -0.17
Stochastic Oscillator 42.97 35.42

Price Performance

Historical Comparison
LOMA
CGEM

About LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS

Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The Group is engaged in the production and distribution of cement, masonry cement, concrete, limestone, and aggregates, operates a railway concession to provide transportation services, and is also engaged in the industrial waste recycling business. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: